| Autor: |
Seneviratne, Janith A., Carter, Daniel R., Mittra, Rituparna, Gifford, Andrew, Kim, Patrick Y., Luo, Jie‐Si, Mayoh, Chelsea, Salib, Alice, Rahmanto, Aldwin S., Murray, Jayne, Cheng, Ngan C., Nagy, Zsuzsanna, Wang, Qian, Kleynhans, Ane, Tan, Owen, Sutton, Selina K., Xue, Chengyuan, Chung, Sylvia A., Zhang, Yizhuo, Sun, Chengtao |
| Předmět: |
|
| Zdroj: |
International Journal of Cancer; Apr2023, Vol. 152 Issue 7, p1399-1413, 15p |
| Abstrakt: |
The mitochondrion is a gatekeeper of apoptotic processes, and mediates drug resistance to several chemotherapy agents used to treat cancer. Neuroblastoma is a common solid cancer in young children with poor clinical outcomes following conventional chemotherapy. We sought druggable mitochondrial protein targets in neuroblastoma cells. Among mitochondria‐associated gene targets, we found that high expression of the mitochondrial adenine nucleotide translocase 2 (SLC25A5/ANT2), was a strong predictor of poor neuroblastoma patient prognosis and contributed to a more malignant phenotype in pre‐clinical models. Inhibiting this transporter with PENAO reduced cell viability in a panel of neuroblastoma cell lines in a TP53‐status‐dependant manner. We identified the histone deacetylase inhibitor, suberanilohydroxamic acid (SAHA), as the most effective drug in clinical use against mutant TP53 neuroblastoma cells. SAHA and PENAO synergistically reduced cell viability, and induced apoptosis, in neuroblastoma cells independent of TP53‐status. The SAHA and PENAO drug combination significantly delayed tumour progression in pre‐clinical neuroblastoma mouse models, suggesting that these clinically advanced inhibitors may be effective in treating the disease. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text